SERA vs. XGN, DCGO, KDLY, EUDA, CORBF, ATPC, QIPT, BMGL, PIII, and OPGN
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Exagen (XGN), DocGo (DCGO), Kindly MD (KDLY), EUDA Health (EUDA), Global Cord Blood (CORBF), Agape ATP (ATPC), Quipt Home Medical (QIPT), Basel Medical Group (BMGL), P3 Health Partners (PIII), and OpGen (OPGN). These companies are all part of the "healthcare" industry.
Sera Prognostics vs.
Exagen (NASDAQ:XGN) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
Exagen received 18 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 62.22% of users gave Exagen an outperform vote while only 37.04% of users gave Sera Prognostics an outperform vote.
75.3% of Exagen shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 13.5% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Exagen has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
In the previous week, Sera Prognostics had 5 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Sera Prognostics and 1 mentions for Exagen. Exagen's average media sentiment score of 1.89 beat Sera Prognostics' score of 0.04 indicating that Exagen is being referred to more favorably in the media.
Sera Prognostics has a net margin of 0.00% compared to Exagen's net margin of -30.36%. Sera Prognostics' return on equity of -51.73% beat Exagen's return on equity.
Exagen currently has a consensus target price of $7.50, suggesting a potential upside of 1.90%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Sera Prognostics.
Summary
Exagen beats Sera Prognostics on 12 of the 18 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
This page (NASDAQ:SERA) was last updated on 6/11/2025 by MarketBeat.com Staff
